Depression with anhedonia features
Conditions
Interventions
Group C:Single-target iTBS 2
Group A:Dual-target iTBS
Group B:Single-target iTBS 1
Group D:Sham iTBS (dual targets)
Sponsors
The Second Xiangya Hospital of Central South Univercity
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 45 years old, Han ethnicity, right-handed; 2. Diagnosed by at least two psychiatrists, meeting the diagnostic criteria for Major Depressive Disorder (MDD) as per the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM5), with a MADRS score of >= 20 or an HAMD-17 score of >= 17; 3. Evaluated by psychiatrists as having significant anhedonia symptoms, and meeting the standards on two anhedonia self-assessment scales, the score of the Shyness-Hamilton Anhedonia Scale - Chinese Version (SHAPS-C) is >= 20 and the score of the Chinese Version of the Pleasant Emotion Experience Scale (TEPS-C) is <= 76; 4. The types and doses of medication remained unchanged during the 4 weeks before treatment and throughout the entire study period; 5. The score of item 10 of the MADRS is <= 4.
Exclusion criteria
Exclusion criteria: 1.A history of epilepsy, seizures, stroke, or other serious organic brain diseases; 2.Presence of severe infectious diseases, malignant tumors, or other major unstable medical conditions; 3.Intellectual disability or developmental delay, presence of psychotic symptoms, or meeting the diagnostic criteria for other psychiatric disorders; 4.A history of substance abuse or psychoactive substance use; 5.Presence of intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes), or any other metallic objects in or near the head that cannot be safely removed (excluding dental fillings); 6.Contraindications to MRI or structural intracranial abnormalities detected on MRI; 7.Pregnant or breastfeeding women; 8.Receipt of electroconvulsive therapy (ECT) within the past 6 months, or transcranial magnetic stimulation (TMS) within the past 3 months; 9.Current daily use of lorazepam > 2 mg (or an equivalent dose), or use of antiepileptic drugs at any dose; 10.Presence of strong suicidal ideation, or a MADRS item 10 score > 4.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chansges of MARDS scores;Changes of TEPS-C scores;Changes of brain functions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of HAMD-17 and SHAPS scores;Cognition evaluation; | — |
Countries
China
Contacts
Public ContactYangpan Ou;Wenbin Guo
The Second Xiangya Hospital of Central South Univercity
Outcome results
None listed